Please assess the completion status of the following clinical trial:

Trial Title: Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women who are 20 - 75 years old~* HbA1c of ≥7.0% and \<10.5%~* FPG of ≤ 270 mg/dL~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 8 weeks before run-in period~Exclusion Criteria:~* Patients with type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes~* Patients with serious diabetic complications~* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification~* Patients with severe hepatic disorder or severe renal disorder.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Teneligliptin + Canagliflozin (Type: EXPERIMENTAL): Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin.
- Placebo + Canagliflozin (Type: PLACEBO_COMPARATOR): Patients receive placebo for 24 weeks in combination with Canagliflozin.

Based on this trial design, predict the completion outcome and termination type (if applicable).